John Quamina

Medical device manufacture and point of care supply company to worldwide veterinary markets with an intent, through technology licensing, to expand into to the human clinical point of care arena. First technology application: Urinary Tract Infection (UTI) technology which is at allowed for issuance​ stage. Technology: ATP Bioluminescence rapid Point of Care Detection & Management (Antibiotic Susceptibility) of UTI 2 -test system: Test 1: detection of UTI in companion animal and human urine (5 mins) Test 2: Antibiotic Susceptibility - to provide the investigating physician with data to be able to prescribe, with confidence, an antibiotic to treat the identified infection

Hi, we’re Tails.com. A pet food subscription company with a big mission. We believe there should be no average dog food because no dog is average. So we deliver 100% tailored nutrition to each and every dog we serve. It all starts with a few simple questions about your dog’s age, breed, activity level and flavour preferences. Then our experts create a one-in-a-million kibble blend – just for them. Everything they need and a taste they love, delivered to your door every month. It’s pretty clever stuff. We’re cooking up big plans. Having created an entirely new category in pet food, we’re scaling fast in the UK and Europe – backed by Purina, one of the world’s largest pet food companies. In 2024 we became B Corp certified. But its more than a badge, its how we operate. Every member of our team is committed to upholding high social and environmental standards, to create a better world for dogs - and humans - for generations to come. We’re working together towards a common goal – to change the world of pet food for good.

Accenture helps the world’s leading enterprises reinvent by building their digital core and unleashing the power of AI to create value at speed for organizations across industries. Our strategy is to be the reinvention partner of choice for our clients and lead in the safe, widespread adoption of AI, and to be the most client-focused, AI-enabled, great place to work in the world. We bring together the talent of our approximately 786,000 people with proprietary assets and platforms, deep process and industry expertise, and leading ecosystem relationships to deliver end-to-end solutions and measurable outcomes at scale. Through our Reinvention Services, we offer broad expertise across Cybersecurity, Digital Core, Finance, Industry and Enterprise, Song, Supply Chain and Engineering, and Talent, with advanced capabilities in AI and Data, Industry and Process, and Technology. We serve approximately 9,000 clients and generated approximately $70 billion in FY25 revenue. Visit us at accenture.com. This LinkedIn company page is moderated. When engaging with Accenture, we encourage everyone to: - Use common courtesy and be respectful of others. - Create your own original content and avoid content that you know to be fraudulent. - Never repost someone elses copyrighted work, unless you have permission. - Never post personal, identifying, or confidential information. We reserve the right to delete comments or posts we deem to be: - Profane, obscene, inappropriate, offensive, abusive material. - Spam, repeated comments and commercial messages and personal advertisements. - Discriminatory or that contain hateful speech of any kind regarding age, gender, race, religion, nationality, sexual orientation, gender identity or disability. - Threats; personal attacks; abusive, defamatory, derogatory, or inflammatory language; or stalking or harassment of any individual, entity or organization. - False, inaccurate, libelous, or otherwise misleading in any way.

Medical device manufacture and point of care supply company to worldwide veterinary markets with an intent, through technology licensing, to expand into to the human clinical point of care arena. First technology application: Urinary Tract Infection (UTI) technology which is at allowed for issuance​ stage. Technology: ATP Bioluminescence rapid Point of Care Detection & Management (Antibiotic Susceptibility) of UTI 2 -test system: Test 1: detection of UTI in companion animal and human urine (5 mins) Test 2: Antibiotic Susceptibility - to provide the investigating physician with data to be able to prescribe, with confidence, an antibiotic to treat the identified infection

Hi, we’re Tails.com. A pet food subscription company with a big mission. We believe there should be no average dog food because no dog is average. So we deliver 100% tailored nutrition to each and every dog we serve. It all starts with a few simple questions about your dog’s age, breed, activity level and flavour preferences. Then our experts create a one-in-a-million kibble blend – just for them. Everything they need and a taste they love, delivered to your door every month. It’s pretty clever stuff. We’re cooking up big plans. Having created an entirely new category in pet food, we’re scaling fast in the UK and Europe – backed by Purina, one of the world’s largest pet food companies. In 2024 we became B Corp certified. But its more than a badge, its how we operate. Every member of our team is committed to upholding high social and environmental standards, to create a better world for dogs - and humans - for generations to come. We’re working together towards a common goal – to change the world of pet food for good.

Capco, a Wipro company, is a global technology and management consultancy specializing in driving digital transformation in the financial services industry. With a growing client portfolio comprising of over 100 global organizations, Capco operates at the intersection of business and technology by combining innovative thinking with unrivalled industry knowledge to deliver end-to-end data-driven solutions and fast-track digital initiatives for banking and payments, capital markets, wealth and asset management, insurance, and the energy sector. Capco’s cutting-edge ingenuity is brought to life through its Innovation Labs and award-winning Be Yourself At Work culture and diverse talent.